Skip to main content

Table 2 Original data extracted from included studies

From: The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

Study

Patients

Survival outcomes

Drug response

Grade 3-4 AEs %

mOS (months)

mPFS (months)

OSR-1y

PFSR-6m

ORR

DCR

CR

PR

SD

mDOR (months)

Ongoing response

2020

Charles [12]

Arm A (n = 228)

10.8 (9.2-12.9)

4.5 (4.3-5.4)

45.10%

34.20%

70.60%

88.20%

1.80%

68.90%

17.50%

4.2 (1.0-26.0)

NR

76.70%

Arm B (n = 225)

9.7 (8.6-10.7)

4.3 (4.2-4.4)

39.60%

NR

61.80%

86.70%

0.90%

60.90%

24.90%

3.7 (1.4-25.8)

19.30%

74.90%

2017

Ott [13]

24

9.7 (4.1-NR)

1.9 (1.7-5.9)

37.70%

29.20%

33.30%

37.60%

4.20%

29.20%

4.20%

19.4 (3.6-20.0)

8.30%

8.30%

2018

Shirish [14]

45

9.6 (7.0-12.0)

1.4 (1.3-2.8)

37.00%

20.00%

11.10%

NR

2.20%

8.90%

NR

10.8 (5.8-NR)

NR

8.90%

2019

Kim [15]

26

9.1 (6.5–15.0)

5.0 (2.7–6.7)

40.70%

34.60%

23.10%

80.80%

3.90%

19.20%

57.70%

9.1 (3.6–11.6)

NR

34.60%

2019

Welsh [16]

33

8.4 (6.7-10.1)

6.1 (4.1–8.1)

29.20%

51.50%

13.16%

33%

3%

12%

18%

NR

NR

6.00%

2020

Welsh [17]

40

39.5 (8.0–71.0)

19.7 (8.8–30.5)

74.70%

80%

78.79%

97%

9.10%

69.70%

18.20%

NR

3.30%

15.00%

  1. Abbreviations: CR complete response, DCR disease control rate, Grade 3–4 AEs grade 3–4 treatment-related adverse effects, mOS median overall survival, mPFS median progression-free survival, mDOR median duration of response, NR no relevant statistic data, ORR objective response rate, OSR-1y 1-year overall survival rate, PFSR-6m progression-free survival rate at 6 months, PR partial response, SD stable disease